What is CellType's biggest risk?

The biggest risk is that CellType's only pharma relationship, a non-binding MOU with Senhwa Biosciences signed March 2026, has not converted into a paying or data-sharing contract. Its technology is built on Google's open-sourced C2S-Scale model, released 2025-10-15, with no licensing lock, meaning larger, better-capitalized teams, including Google itself, face little to stop them from copying its approach on the same open model.

Is CellType in financial trouble?

CellType has raised only $500K total as of 2026-03-17, which is a fraction of what named category competitors have secured, such as Isomorphic Labs' $2.1B Series B closed May 2026. It has no signed paying customer yet, only an unsigned March 2026 MOU with Senhwa Biosciences, so its commercial traction sits close to zero even though it is not formally reporting distress.

Who are CellType's biggest competitors?

Named rivals in the same biology-AI drug discovery space include Isomorphic Labs, which raised a $2.1B Series B in May 2026 and holds roughly $3B in pharma deals, plus Chai Discovery, which closed a $400M Series C at a $3.8B valuation with Lilly, Pfizer, and Novartis as partners. Insilico Medicine is also ahead clinically, with its Rentosertib compound reaching Phase III trials in July 2026, while CellType still operates with a 2-person team and $500K in funding as of 2026-07-22.

Is CellType at risk from AI?

Yes, CellType's core technology runs on Google's C2S-Scale model, a 27 billion parameter model Google open-sourced on 2025-10-15, which anyone including Google itself can build the same agent layer on top of. There is no licensing lock on this model, which as of the July 2026 assessment leaves almost nothing to stop replication of its technical approach by larger, better-funded teams.

Does CellType have any real customers or scientific results yet?

CellType has no signed paying customer as of the July 2026 assessment, only a non-binding March 2026 MOU with Senhwa Biosciences covering the compound CX-4945. On the science side, a validated hypothesis from its platform showed an approximately 50% increase in antigen presentation as of 2025-10-15, which is a technical result rather than a commercial one.

What should I watch for next with CellType?

By Q4 2026, watch whether the Senhwa Biosciences MOU converts into a binding, revenue-sharing contract, since that is currently the only pharma relationship CellType has. By 2027-01, watch whether CellType announces a second named pharma partner beyond Senhwa, which would be the first sign it can compete for deals against better-funded rivals like Isomorphic Labs and Chai Discovery.

YC Winter 2026 · United States

CellType

Two-person startup using LLMs to simulate cell biology for drug discovery.

Losing its protection

Assessed 31 July 2026 · Evidence as of 31 July 2026

The structural protection is eroding.

On the recordSince 31 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Window for Senhwa MOU to convert into a disclosed, milestone-bearing licensing deal

The call

CellType's science is real but unprotected, sitting one step behind the same lab that could rebuild its work without it.

CellType built software that uses artificial intelligence to predict how cells behave during drug development. The problem is that CellType published its exact method with Google DeepMind as a co-author, and Google built it using free, open-source technology that anyone can access. Since Google owns both CellType's research and Isomorphic Labs, a competitor with billions of dollars in funding, Google could simply build the same thing itself and sell it directly to pharmaceutical companies without needing CellType. The company has two employees, almost no money in the bank, and needs to turn its early partnerships with drug makers like Senhwa into real, paid contracts within the next year, before either Google ships a competing product or other well-funded AI companies like Recursion or Insilico Medicine take over the market.

Why

AI pressure: Google DeepMind (co-developer of CellType's Cell2Sentence model). DeepMind co-authored CellType's core model and owns Isomorphic Labs, the rival best placed to absorb this method itself. Could AI do the core job? Yes, likely.

Bigger players: Isomorphic Labs, Insilico Medicine, Recursion/Exscientia. Rivals with $1 to 3B in funding already run clinical stage AI drug programs, dwarfing CellType's two person team and $500K. Could a giant copy it? Yes, easily.

What protects it. A published Cell2Sentence method and Yale origins give it a technical head start, but no exclusive data or signed contracts lock anything in.

What would change this call

Senhwa MOU converts (or fails to convert) to a disclosed, milestone-bearing licensing deal within 6-9 months. Shows whether CellType can turn its one named partnership into real revenue.
Google DeepMind or Isomorphic Labs announces its own cell-state simulation offering sold directly to pharma. Would show the co-owner of CellType's core method commercializing it as a direct rival.
Boehringer Ingelheim or Bristol Myers Squibb publicly confirm (or deny) a paid pilot with CellType. Would verify or debunk CellType's self-reported pharma pilot claims.

Key numbers

$500K total funding raised (2026-03-17)
2 founders, no other disclosed staff (2026-05-12)
27B-parameter model built on Google's Gemma (2026-05-12)

Named risks

Only $500,000 raised with two employees, implying roughly one year of runway as of mid-2026. Severity: high
Core Cell2Sentence method co-developed with Google DeepMind, which also owns competitor Isomorphic Labs. Severity: high
Claimed pharma pilots (Boehringer $80K, BMS $40K, Top-10 pharma inbound) are self-reported and unconfirmed by third parties. Severity: medium
No AI-discovered drug has reached market approval industry-wide as of 2026-05-25, pressuring category sentiment. Severity: medium
Well-capitalized rivals with $1B-3B in funding are actively competing for the same pharma partnerships. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Isomorphic Labs	losing to	Isomorphic reported ~$3B in Lilly/Novartis deals and >$2B funding round as of 2026-07-20 vs CellType's $500K
Insilico Medicine	losing to	Insilico signed Eli Lilly licensing deal Nov 2025 and published Phase 2a IPF results in Nature Medicine
Recursion Pharmaceuticals	losing to	Recursion CEO said 8 AI-discovered programs reached clinical testing by late 2025
Xaira Therapeutics	losing to	Xaira has $1B committed funding vs CellType's $500K, per 2026-07-20 report
Google DeepMind	contesting	DeepMind co-authored CellType's core Cell2Sentence method and owns rival Isomorphic Labs

Questions people ask

What is CellType's biggest risk?: The biggest risk is that CellType's only pharma relationship, a non-binding MOU with Senhwa Biosciences signed March 2026, has not converted into a paying or data-sharing contract. Its technology is built on Google's open-sourced C2S-Scale model, released 2025-10-15, with no licensing lock, meaning larger, better-capitalized teams, including Google itself, face little to stop them from copying its approach on the same open model.
Is CellType in financial trouble?: CellType has raised only $500K total as of 2026-03-17, which is a fraction of what named category competitors have secured, such as Isomorphic Labs' $2.1B Series B closed May 2026. It has no signed paying customer yet, only an unsigned March 2026 MOU with Senhwa Biosciences, so its commercial traction sits close to zero even though it is not formally reporting distress.
Who are CellType's biggest competitors?: Named rivals in the same biology-AI drug discovery space include Isomorphic Labs, which raised a $2.1B Series B in May 2026 and holds roughly $3B in pharma deals, plus Chai Discovery, which closed a $400M Series C at a $3.8B valuation with Lilly, Pfizer, and Novartis as partners. Insilico Medicine is also ahead clinically, with its Rentosertib compound reaching Phase III trials in July 2026, while CellType still operates with a 2-person team and $500K in funding as of 2026-07-22.
Is CellType at risk from AI?: Yes, CellType's core technology runs on Google's C2S-Scale model, a 27 billion parameter model Google open-sourced on 2025-10-15, which anyone including Google itself can build the same agent layer on top of. There is no licensing lock on this model, which as of the July 2026 assessment leaves almost nothing to stop replication of its technical approach by larger, better-funded teams.
Does CellType have any real customers or scientific results yet?: CellType has no signed paying customer as of the July 2026 assessment, only a non-binding March 2026 MOU with Senhwa Biosciences covering the compound CX-4945. On the science side, a validated hypothesis from its platform showed an approximately 50% increase in antigen presentation as of 2025-10-15, which is a technical result rather than a commercial one.
What should I watch for next with CellType?: By Q4 2026, watch whether the Senhwa Biosciences MOU converts into a binding, revenue-sharing contract, since that is currently the only pharma relationship CellType has. By 2027-01, watch whether CellType announces a second named pharma partner beyond Senhwa, which would be the first sign it can compete for deals against better-funded rivals like Isomorphic Labs and Chai Discovery.

Timeline

2026-03-18Latest recorded seed/note funding round for CellType, per CBInsights
2026-03-02Senhwa Biosciences signs MOU with CellType for CX-4945 2.0 development
2026-02-19Y Combinator backs CellType as Yale spinout in W26 batch
2026-02-17CellType publicly unveiled via Launch YC page
2025-01CellType founded (year cited, exact month not specified)
2024-10Patent US20250139386A1 covering CellType's method filed
2024-01Cell2Sentence (C2S) method published at ICML 2024 (year only)

Head to head

CellType vs Insilico Medicine CellType vs Isomorphic Labs

Revision history

31 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

OctaPulse The Token Company Crow